Incannex Healthcare (IHL) partners with Sleep Research Centre at UWA to expand the IHL-42X OSA study program
2021-05-11 05:00:50 (AET) by Ring Zhang 571
Incannex Healthcare Limited (ASX: IHL), an ASX-Listed pharmaceutical development company, today announced its partnership agreement with the University of Western Australia Centre to expand the number of clinical sites for its ongoing dose-finding trial, which is investigating the effect of drug candidate IHL-42X in adults diagnosed with Obstructive Sleep Apnoea (‘OSA’).
Incannex Healthcare Limited (ASX: IHL) , an ASX-Listed pharmaceutical development company, today announced its partnership agreement with the University of Western Australia Centre to expand the number of clinical sites for its ongoing dose-finding trial, which is investigating the effect of drug candidate IHL-42X in adults diagnosed with Obstructive Sleep Apnoea (OSA).
The stock price of IHL was down by 3.17% compared to the close price yesterday.
The drug developer is currently conducting the phase 2b trial, which started late last year, at The Alfred Hospital in Melbourne with initial results pending. With the new partnership, the trial is now considered a multi-site study with extra medical and scientific professionals contributing to the program.
Patients diagnosed with OSA are treated with IHL-42X at 3 different dose levels in a randomised, double-blind and placebo-controlled cross over study to assess the therapeutic benefit of the drug. The primary endpoint in the trial is the reduction in Apnoea Hypopnea Index (‘AHI’), compared to baseline, or pre-treatment, levels. Participants are also monitored for improvements in alertness, daytime sleepiness, mood, and quality of life.
When commenting on the new partner, Incannex emphasised that ‘the Centre for Sleep Science at the University of Western Australia is a world-class facility at the forefront of sleep research and sleep education, which ensures it works towards its vision of providing evidence-based education and conducting quality, clinically relevant research which will ultimately improve sleep health in the community.’
Director of the Centre for Sleep Science at the UWA, who also leads the sleep physiology research team at the West Australian Sleep Disorders Research Institute (‘WASDRI’) at Sir Charles Gairdner Hospital, will supervise the study.
Dr Jen Walsh said; “Given the number of people with OSA and the proportion unable to tolerate existing therapies, it is exciting to be working with Incannex on this trial of an alternate treatment option. Even patients who can tolerate existing therapies for their OSA would sometimes like the option to take a medication rather than sleep with a device.”
About Obstructive Sleep Apnoea (OSA)
Four in 10 Australian adults experience regular poor sleep, the consequences of which can have significant impacts on health, performance, and society. OSA is a highly prevalent condition affecting approximately 30M adults in the USA, yet treatment option is very limited. The main current treatment option for OSA is the mechanical CPAP device (Figure 1), users experience discomfort resulting from pressurised air being pumped into the patient’s nose and/or mouth during sleep.
Figure 1 mechanical CPAP device
OSA represents a major market opportunity of IHL and is one of six medicinal cannabinoid or psychedelic therapies under development at the company. IHL anticipates greatly improved patient treatment compliance and outcomes from a pharmaceutical product, which could be IHL-42X should it prove successful under clinical assessment.
【See more information about IHL, please click IHL 】
Incannex Healthcare Limited (ASX: IHL) 11.05.2021 ASX announcement: IHL-42X OSA Update